Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.
1. A method for modulating the expression of a first gene in a cell, wherein said first gene contains expanded CAG repeats with a repeat number more than 36, said method comprising:
suppressing the expression of a second gene,
wherein said second gene is one selected from the group consisting of: SPT4, SPT5, SUPT4H and SUPT5H.
2. The method of claim 1 , wherein said first gene is selected from the group consisting of: SCA1, SCA2, SCA3, SCA7, SCA17, DRPLA, AR, and Htt gene.
3. The method of claim 1 , wherein said first gene encodes a protein containing an expanded polyglutamine stretch with more than 36 glutamine residues and form aggregates in the cell.
4. The method of claim 1 , wherein said suppressing step is performed by a gene suppressing method selected from gene knockdown, gene knockout, chemical inhibitor or a combination thereof.
5. The method of claim 1 , wherein said cell is an animal cell or an yeast cell.
6. The method of claim 5 , wherein the cell is mammalian cell.
7. A method of treating a polyglutamine disease, comprising:
applying the method of claim 1 to a subject suffering from said polyglutamine disease.
8. The method of claim 7 , wherein said polyglutamine disease is selected from the group consisting of Spino-cerebellar ataxia type 1, 2, 3, 7, 17, dentatorubral- pallidoluysian atrophy, spinal and bulbar muscular atrophy, and Huntington's disease.